URGN Valuation
Urogen Pharma Ltd
$
19.770
- Overview
- Forecast
- Valuation
- Earnings
URGN Relative Valuation
URGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, URGN is overvalued; if below, it's undervalued.
Historical Valuation
Urogen Pharma Ltd (URGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.71 is considered Undervalued compared with the five-year average of -3.63. The fair price of Urogen Pharma Ltd (URGN) is between 365.97 to 384.11 according to relative valuation methord. Compared to the current price of 20.11 USD , Urogen Pharma Ltd is Undervalued By 94.5%.
Relative Value
Fair Zone
365.97-384.11
Current Price：20.11
94.5%
Undervalued
-9.94
PE
1Y
3Y
5Y
Trailing
Forward
-9.38
EV/EBITDA
Urogen Pharma Ltd. (URGN) has a current EV/EBITDA of -9.38. The 5-year average EV/EBITDA is -3.78. The thresholds are as follows: Strongly Undervalued below -8.07, Undervalued between -8.07 and -5.93, Fairly Valued between -1.64 and -5.93, Overvalued between -1.64 and 0.50, and Strongly Overvalued above 0.50. The current Forward EV/EBITDA of -9.38 falls within the Strongly Undervalued range.
-13.37
EV/EBIT
Urogen Pharma Ltd. (URGN) has a current EV/EBIT of -13.37. The 5-year average EV/EBIT is -3.75. The thresholds are as follows: Strongly Undervalued below -8.08, Undervalued between -8.08 and -5.92, Fairly Valued between -1.59 and -5.92, Overvalued between -1.59 and 0.58, and Strongly Overvalued above 0.58. The current Forward EV/EBIT of -13.37 falls within the Strongly Undervalued range.
4.71
PS
Urogen Pharma Ltd. (URGN) has a current PS of 4.71. The 5-year average PS is 4.79. The thresholds are as follows: Strongly Undervalued below -0.52, Undervalued between -0.52 and 2.13, Fairly Valued between 7.44 and 2.13, Overvalued between 7.44 and 10.09, and Strongly Overvalued above 10.09. The current Forward PS of 4.71 falls within the Historic Trend Line -Fairly Valued range.
-11.06
P/OCF
Urogen Pharma Ltd. (URGN) has a current P/OCF of -11.06. The 5-year average P/OCF is -3.17. The thresholds are as follows: Strongly Undervalued below -9.72, Undervalued between -9.72 and -6.45, Fairly Valued between 0.10 and -6.45, Overvalued between 0.10 and 3.38, and Strongly Overvalued above 3.38. The current Forward P/OCF of -11.06 falls within the Strongly Undervalued range.
-120.55
P/FCF
Urogen Pharma Ltd. (URGN) has a current P/FCF of -120.55. The 5-year average P/FCF is -7.80. The thresholds are as follows: Strongly Undervalued below -30.97, Undervalued between -30.97 and -19.39, Fairly Valued between 3.78 and -19.39, Overvalued between 3.78 and 15.37, and Strongly Overvalued above 15.37. The current Forward P/FCF of -120.55 falls within the Strongly Undervalued range.
Urogen Pharma Ltd (URGN) has a current Price-to-Book (P/B) ratio of -9.50. Compared to its 3-year average P/B ratio of -3.08 , the current P/B ratio is approximately 208.77% higher. Relative to its 5-year average P/B ratio of 0.27, the current P/B ratio is about -3644.00% higher. Urogen Pharma Ltd (URGN) has a Forward Free Cash Flow (FCF) yield of approximately -14.64%. Compared to its 3-year average FCF yield of -25.51%, the current FCF yield is approximately -42.62% lower. Relative to its 5-year average FCF yield of -28.53% , the current FCF yield is about -48.70% lower.
-9.50
P/B
Median3y
-3.08
Median5y
0.27
-14.64
FCF Yield
Median3y
-25.51
Median5y
-28.53
Competitors Valuation Multiple
The average P/S ratio for URGN's competitors is 364.96, providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN) exhibits a P/S ratio of 4.71, which is -98.71% above the industry average. Given its robust revenue growth of 10.83%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of URGN increased by 44.57% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -152.89 to -206.24.
The secondary factor is the Revenue Growth, contributed 10.83%to the performance.
Overall, the performance of URGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
VBNK
Versabank
10.650
USD
0.00%
SAGE
SAGE Therapeutics Inc
8.685
USD
-0.23%
VALU
Value Line Inc
38.960
USD
0.00%
BAND
Bandwidth Inc
14.440
USD
0.00%
NRIM
Northrim BanCorp Inc
86.790
USD
-1.09%
SVC
Service Properties Trust
2.460
USD
-3.53%
TRC
Tejon Ranch Co
17.550
USD
+0.46%
CLDT
Chatham Lodging Trust
7.140
USD
-1.79%
MERC
Mercer International Inc
3.080
USD
+0.98%
BIOX
Bioceres Crop Solutions Corp
2.920
USD
-6.41%
FAQ
Is Urogen Pharma Ltd (URGN) currently overvalued or undervalued?
Urogen Pharma Ltd (URGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.71 is considered Undervalued compared with the five-year average of -3.63. The fair price of Urogen Pharma Ltd (URGN) is between 365.97 to 384.11 according to relative valuation methord. Compared to the current price of 20.11 USD , Urogen Pharma Ltd is Undervalued By 94.50% .
What is Urogen Pharma Ltd (URGN) fair value?
How does URGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Urogen Pharma Ltd (URGN) as of Aug 14 2025?
What is the current FCF Yield for Urogen Pharma Ltd (URGN) as of Aug 14 2025?
What is the current Forward P/E ratio for Urogen Pharma Ltd (URGN) as of Aug 14 2025?